Wall Street Analysts Believe CorMedix (CRMD) Could Rally 45.63%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 45.6% in CorMedix (CRMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Why CorMedix (CRMD) Might be Well Poised for a Surge
CorMedix (CRMD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
CorMedix, Inc. (CRMD) Q2 2025 Earnings Call Transcript
CorMedix, Inc. (NASDAQ:CRMD ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Joseph Todisco - CEO & Director Matthew T. David - Executive VP & CFO Conference Call Participants Anish Nikhanj - RBC Capital Markets, Research Division Brandon Richard Folkes - H.C.
CorMedix to Buy Melinta Therapeutics for $300 Million
The buyer said the deal adds six marketed infectious-disease products to its offerings.
CorMedix (CRMD) Surpasses Q2 Earnings and Revenue Estimates
CorMedix (CRMD) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.2 per share. This compares to a loss of $0.25 per share a year ago.
CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Q2 Release
CorMedix (CRMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Does CorMedix (CRMD) Have the Potential to Rally 65.64% as Wall Street Analysts Expect?
The mean of analysts' price targets for CorMedix (CRMD) points to a 65.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CorMedix (CRMD) Soars 5.1%: Is Further Upside Left in the Stock?
CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Can CorMedix (CRMD) Keep the Earnings Surprise Streak Alive?
CorMedix (CRMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
CorMedix Seems Significantly Undervalued
CorMedix offers high upside potential with DefenCath, the only FDA-approved catheter lock solution for CRBSI, and a strong financial position. My DCF model shows a base-case fair value of $26.2 per share, representing 110% upside; the options market also signals bullish sentiment. Key risks include reliance on a single product and high market share uncertainty, so I keep my position size small and avoid options due to illiquidity and high premiums.
CorMedix: DefenCath In Exponential Growth Phase With Robust Market Position
I am bullish on CorMedix due to its strong financial turnaround, robust revenue growth, and unique market position. DefenCath, the only FDA-approved antimicrobial catheter lock solution in the US, drives exponential revenue and profitability, with high adoption potential. CRMD's competitive edge lies in its first-mover advantage, high efficacy, and significant penetration in the US dialysis market.
CorMedix: Exceeding Expectations
CorMedix and its flagship product DefenCath have significantly outperformed expectations since commercialization, driving strong stock performance in 2025. DefenCath, approved just over a year ago, is proving highly effective in reducing catheter-related bloodstream infections, supporting its 'best of breed' status. Recent Q1 results beat consensus estimates, and the stock has strong analyst support and some recent upwardly revised price targets, reflecting confidence in continued growth.
